ADC Therapeutics SA

NYSE:ADCT 주식 보고서

시가총액: US$192.4m

ADC Therapeutics 관리

관리 기준 확인 3/4

ADC Therapeutics CEO는 Ameet Mallik, May2022 에 임명되었습니다 의 임기는 2.5 년입니다. 총 연간 보상은 $ 3.78M, 19.1% 로 구성됩니다. 19.1% 급여 및 80.9% 보너스(회사 주식 및 옵션 포함). 는 $ 1.97M 가치에 해당하는 회사 주식의 1.03% 직접 소유합니다. 1.97M. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 4 년입니다.

주요 정보

Ameet Mallik

최고 경영자

US$3.8m

총 보상

CEO 급여 비율19.1%
CEO 임기2.5yrs
CEO 소유권1.0%
경영진 평균 재임 기간2.3yrs
이사회 평균 재임 기간4yrs

최근 관리 업데이트

Recent updates

Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%

Nov 16
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%

ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Jul 18
ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Limiting Concerns On ADC Therapeutics' Prospects

Jun 06

ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues

May 30
ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

May 10
Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

Mar 19

ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

Mar 17
ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

Jan 18
ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial

Dec 29

An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

Dec 14
An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

ADC Therapeutics: Navigating A Swirling Drain

Dec 01

ADC Therapeutics: Slowly Moving Toward Solvency

Aug 29

Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?

Jul 11
Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?

ADC Therapeutics: Maybe A 2024 Story

May 29

Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

May 11
Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

Apr 18
ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

ADC Therapeutics stock slips after pricing stock offering by seller

Feb 02

Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

Jan 16
Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

Jose Carmona joins ADC Therapeutics as CFO

Dec 19

ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M

Nov 08

ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval

Sep 16

ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11

Sep 09

CEO 보상 분석

Ameet Mallik 의 보수는 ADC Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$212m

Jun 30 2024n/an/a

-US$215m

Mar 31 2024n/an/a

-US$227m

Dec 31 2023US$4mUS$721k

-US$240m

Sep 30 2023n/an/a

-US$181m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$200m

Dec 31 2022US$11mUS$475k

-US$157m

보상 대 시장: Ameet 의 총 보상 ($USD 3.78M )은 US 시장( $USD 1.48M ).

보상과 수익: Ameet 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Ameet Mallik (51 yo)

2.5yrs

테뉴어

US$3,779,425

보상

Dr. Ameet Mallik M.B.A., M.S, is Director at ADC Therapeutics SA from June 30, 2022. He has been a Director of Atara Biotherapeutics, Inc. since August 2021. Dr. Mallik serves as Chief Executive Officer at...

리더십 팀

이름위치테뉴어보상소유권
Ameet Mallik
CEO & Director2.5yrsUS$3.78m1.03%
$ 2.0m
Jose Carmona
Chief Financial Officer1.9yrsUS$1.26m0.22%
$ 419.6k
Mohamed Zaki
Chief Medical Officer1.8yrsUS$4.40m0.24%
$ 464.3k
Lisa Kallebo
Corporate Controller & Chief Accounting Officerno data데이터 없음데이터 없음
Michael Mulkerrin
Chief Technical Operations Officer2.8yrs데이터 없음데이터 없음
Patrick van Berkel
Chief Scientific Officer2.8yrs데이터 없음데이터 없음
Amanda Hamilton
Investor Relations Officerno data데이터 없음데이터 없음
Peter Graham
Secretary & Chief Legal Officer2yrs데이터 없음데이터 없음
Eugenia Litz
Vice President of Investor Relations & Corporate Communicationsno data데이터 없음데이터 없음
Kimberly Pope
Senior VP & Chief People Officer4.3yrs데이터 없음데이터 없음
Kristen Harrington-Smith
Chief Commercial Officer2yrs데이터 없음데이터 없음

2.3yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: ADCT 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Ameet Mallik
CEO & Director2.4yrsUS$3.78m1.03%
$ 2.0m
Michael Forer
Board Observer1.4yrsUS$846.56k데이터 없음
Peter Hug
Vice-Chairman & Lead Independent Director5.4yrsUS$212.61k0.15%
$ 283.9k
Ron Squarer
Chairman of the Board4.6yrsUS$526.73k1.6%
$ 3.1m
Jean-Pierre Bizzari
Independent Non-Executive Director2.4yrsUS$197.81k0.059%
$ 113.2k
Tyrell Rivers
Independent Non-Executive Director6.4yrs데이터 없음데이터 없음
Victor Sandor
Independent Non-Executive Director4.6yrsUS$227.72k0.074%
$ 143.3k
Robert Azelby
Independent Director1.4yrsUS$127.67k0.024%
$ 46.4k
Viviane Monges
Independent Non-Executive Director3.4yrsUS$231.33k0.098%
$ 188.6k
Thomas Pfisterer
Non-Independent Director8.1yrsUS$194.30k0.18%
$ 346.1k

4.0yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 이사회: ADCT 의 이사회는 경험(평균 재직 기간 4 년)으로 간주됩니다.